Up­dat­ed: J&J re­turns rights to ear­ly-stage, RNAi NASH can­di­date to Ar­row­head

J&J is hand­ing the rights to a Phase I NASH can­di­date, stem­ming from a 2018 multi­bil­lion-dol­lar deal, back to its de­vel­op­er.

Ar­row­head Phar­ma­ceu­ti­cals said Wednes­day morn­ing that it now re­gained full rights to JNJ-75220795, re­named ARO-PN­PLA3, an RNAi can­di­date be­ing in­ves­ti­gat­ed in NASH that was de­vel­oped with the biotech’s plat­form and de­signed to low­er ex­pres­sion of PN­PLA3 in the liv­er. PN­PLA3 is an en­zyme that is com­mon in pa­tients with the dis­ease and a I148M mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER